arrow
B

Bruno Sangro

instituto de investigacion sanitaria de navarra
H指数:95
被引数:4.9万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

First-line durvalumab and tremelimumab in poor-prognosis unresectable hepatocellular carcinoma: Phase IIIb single-arm SIERRA study

一线度伐利尤单抗和特瑞普利单抗在预后不良的不可切除肝细胞癌中的应用:IIIb期单臂SIERRA研究

2026-10-060
OAAI
Histone methyl-transferase G9a inhibition boosts the efficacy of immune checkpoint inhibitors in experimental hepatocellular carcinoma

组蛋白甲基转移酶G9a抑制增强了免疫检查点抑制剂在实验性肝细胞癌中的疗效

2026-03-310
OAAI
Immunogenicity of neoantigens from hepatocellular carcinoma patients treated with a combined radioimmunotherapy

接受联合放射免疫治疗的肝细胞癌患者来源新抗原的免疫原性

2026-03-180
OA
Trefoil Factor-3 Is a Hypoxia-Triggered Pro-Tumorigenic Factor in Hepatoblastoma

三叶因子-3是缺氧诱导的肝母细胞瘤促肿瘤因子

2026-03-130
OAAI
A liver gene signature links liver cancer risk in chronic viral hepatitis to intrahepatic IgA plasma cells

肝脏基因签名将慢性病毒性肝炎的肝癌风险与肝内IgA浆细胞联系起来

2025-12-190
OAAI
Early Safety Results from the Phase 3b SIERRA Study of Durvalumab and Tremelimumab as First-Line Treatment for Participants with Unresectable Hepatocellular Carcinoma and a Poor Prognosis

IIIb期SIERRA研究早期安全性结果:度伐利尤单抗和特瑞普利单抗作为不可切除肝细胞癌且预后不良患者的一线治疗方案。

2025-12-010
OA
Correction: Imaging in staging, treatment planning, and monitoring of hepatocellular carcinoma for local and locoregional therapies: consensus recommendations from EORTC and ESGAR

更正:EORTC和ESGAR关于局部和局部区域治疗中肝细胞癌分期、治疗计划制定和监测的影像学应用:共识建议

2025-10-310
OA
BCLC strategy for prognosis prediction and treatment recommendations: The 2025 update

用于预后预测和治疗建议的BCLC策略: 2025更新

2025-10-270
PRE
Disparities in access to systemic therapies for patients with hepatocellular carcinoma: an analysis from the International Liver Cancer Association

肝癌患者系统性治疗可及性差异:国际肝病肿瘤协会的分析

2025-07-310
PREAI
Imaging in staging, treatment planning, and monitoring of hepatocellular carcinoma for local and locoregional therapies: consensus recommendations from EORTC and ESGAR

在局部和局部区域治疗中,肝细胞癌分期、治疗计划和监测的影像学应用:EORTC和ESGAR的共识建议

2025-05-230
OA
Five-year overall survival update from the HIMALAYA study of tremelimumab plus durvalumab in unresectable HCC

HIMALAYA研究五-year总体生存率更新:曲美木单抗联合度伐利尤单抗治疗不可切除性HCC

2025-04-110
OAAI